Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry
- 1 March 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 324-329
- https://doi.org/10.1016/j.jcf.2020.08.001
Abstract
No abstract availableKeywords
Funding Information
- Teva Pharmaceutical Industries
This publication has 16 references indexed in Scilit:
- Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross‐sectional studyPharmacoepidemiology and Drug Safety, 2019
- Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industryThe Lancet. Respiratory Medicine, 2018
- Data Resource Profile: The UK Cystic Fibrosis RegistryInternational Journal of Epidemiology, 2017
- Inhaled therapy in cystic fibrosis: agents, devices and regimensBreathe, 2015
- Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic FibrosisDrugs, 2014
- Treatment of lung infection in patients with cystic fibrosis: Current and future strategiesJournal of Cystic Fibrosis, 2012
- State of progress in treating cystic fibrosis respiratory diseaseBMC Medicine, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009